Dantrelax

Dantrolene Sodium

Method of action: Miorelaxant, Skeletal Muscle Relaxant

Treatment option: Spasticity

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dantrelax

Quick Facts

Property	Description
Active ingredient	Dantrolene Sodium
Form	Capsules (Oral), Powder for solution (Intravenous)
Pharmacological class	Skeletal Muscle Relaxant
Common use	Reduction of muscle spasticity and rigidity
Origin	Synthetic drug, Hydantoin derivative

Defining Dantrelax: What Type of Medicine is Dantrolene Sodium?

Dantrelax is a prescription-only medication whose active component is Dantrolene Sodium, primarily classified as a skeletal muscle relaxant. This drug is a synthetic compound, specifically a Hydantoin derivative, which distinguishes its chemical structure and pharmacological action within its class. This medication is designed to address muscle issues directly at the source, a differentiation clinically recognized for its unique mechanism.

This substance represents a unique pharmaceutical entity because it is a single-ingredient product, deliberately manufactured to provide a highly targeted effect. The Dantrolene Sodium component belongs to the drug class of direct-acting spasmolytic agents, which signifies that its primary therapeutic influence is exerted directly on the muscle fibers themselves, not through the nervous system. It serves as a primary agent used to manage acute malignant hyperthermia episodes by targeting excessive calcium release in muscle cells. This unique, peripheral action is the key factor differentiating it from central muscle relaxants, underscoring its importance in critical care scenarios.

Composition, Forms, and General Use

Dantrolene Sodium is available in two distinct pharmaceutical preparations: capsules for oral administration and a sterile powder for solution intended for parenteral (intravenous) administration. The general purpose of this medicine is to address and reduce excessive or uncontrolled muscle tightening and rigidity, such as that seen in certain long-term neurological conditions.

The availability of both forms ensures clinical utility across varied needs; the capsules are designed for ongoing, systemic management, while the powder for solution is vital in acute care settings where rapid and reliable systemic delivery is essential. Dantrolene Sodium achieves its general benefit by regulating the release of calcium within the muscle cell. By inhibiting the release of this chemical signal, it effectively relaxes the muscle fiber, directly stopping the unwanted contraction and reducing spasticity without relying on altering nerve signals from the brain.

What side effects are possible with Dantrelax?

Possible Side Effects and Safety Information

The official safety profile of Dantrolene Sodium is structured around classifications detailed in regulatory documents, identifying possible adverse reactions by frequency and affected organ system.

Documented Adverse Reaction Frequency

Adverse reactions are categorized based on incidence rates found in clinical use:

Classification	Examples of Documented Adverse Reactions
Very Common (≥ 10%)	Drowsiness (Somnolence), Speech disturbance (Dysphonia)
Common (1% to 10%)	Nausea, Vomiting, Headache, Dizziness, Muscular weakness, Hepatotoxicity, Seizure, Pericarditis
Rare (1 in 1,000 to 10,000)	Aplastic anaemia, Pleural effusion, Gastrointestinal hemorrhage

System-Organ Class and Serious Safety Concerns

Adverse reactions are officially grouped into System-Organ Classes (SOCs), with frequent effects noted in the Nervous System (e.g., dizziness, somnolence) and the Musculoskeletal System (e.g., muscle weakness, loss of grip strength).

Hepatobiliary Disorders represent the most significant safety concern. Regulatory labels highlight the potential for Fatal and Non-Fatal Hepatic Failure (symptomatic hepatitis), which is classified as a serious adverse reaction. This risk is most frequently observed between the third and twelfth month of continuous therapy.

Other serious adverse events documented in official sources include Cardiovascular Collapse (a reported risk when the intravenous form is combined with certain calcium channel blockers), Pleural Effusion, and Pericarditis.

Regulatory Safety Considerations

The official labeling includes specific restrictions. Oral use is contraindicated in patients with active hepatic disease, such as cirrhosis or acute hepatitis. Furthermore, documentation indicates that females and patients over 35 years of age appear to have a greater likelihood of developing drug-induced hepatic disease. Common effects like drowsiness and dizziness are often noted to be more pronounced at the initiation of treatment or following dose increases.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Dantrolene Sodium is documented by regulatory authorities as potentially resulting in severe physiological consequences. Officially reported manifestations include severe muscular weakness, extreme tiredness (lethargy), vomiting, and diarrhea. Patients may also experience alterations in the state of consciousness. A key concern reported in acute overexposure is the potential for crystalluria.

Serious and life-threatening outcomes officially associated with overdose include respiratory depression—a result of the profound muscle weakness—and central nervous system effects such as seizures and coma.

Emergency Action Required

If an overdose is suspected, immediate medical attention must be sought. Regulatory guidance states that emergency services must be called immediately if the person has collapsed, is having a seizure, has trouble breathing, or cannot be awakened. Contacting a poison control helpline is also a required step.

Management and Treatment

The official regulatory profile confirms that no specific antidote is known for a Dantrolene Sodium overdose. Treatment focuses entirely on symptomatic and supportive measures. These measures include maintaining an adequate airway and instituting Electrocardiographic (ECG) monitoring. To avert the possibility of crystalluria, intravenous fluids should be administered in large quantities, and the patient must be carefully observed.

Therapeutic Uses of Dantrelax

Main Uses and Benefits of Dantrelax

Dantrelax is a muscle relaxant specifically indicated for the management of chronic, severe spasticity. Unlike many other muscle relaxants that act on the central nervous system, this medication works directly on the skeletal muscles to reduce contraction and stiffness.

Therapeutic Applications

The primary use of Dantrelax is to alleviate the symptoms of spasticity resulting from various neurological conditions. These include:

Spinal Cord Injury: Management of involuntary muscle spasms and stiffness following trauma to the spinal cord.
Cerebral Palsy: Reduction of muscle tightness to help improve mobility and comfort in patients with permanent movement disorders.
Multiple Sclerosis: Treatment of chronic muscle stiffness and spasms associated with the progression of the disease.
Stroke: Addressing the long-term spasticity that can occur during the recovery phase of a cerebrovascular accident.

Clinical Benefits

By acting directly on the muscle fibers, Dantrelax helps to modify the physical manifestations of spasticity. The goals of treatment typically include:

Reduction of Muscle Stiffness: Decreasing the excessive muscle tone that makes limbs difficult to move.
Improvement in Range of Motion: Facilitating better movement of the joints by relaxing the restrictive tension in surrounding muscles.
Facilitation of Daily Activities: Helping patients perform routine tasks such as dressing, hygiene, or eating by reducing the interference of involuntary spasms.
Enhanced Physical Therapy: Supporting the effectiveness of rehabilitative exercises by making the muscles more pliable and responsive to stretching.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dantrelax (Dantrolene) — Official Regulatory Information

Eligibility for Dantrolene is strictly determined by its formulation and intended use (oral capsule for chronic spasticity versus intravenous injection for malignant hyperthermia crisis).

Contraindications (Must NOT Use):

Formulation	Absolute Contraindications
Oral Capsule	Active hepatic disease (e.g., hepatitis, cirrhosis) due to the risk of severe hepatotoxicity. Patients whose spasticity is required to maintain upright posture, balance, or functional movement. Known hypersensitivity to the drug. Severe cardiovascular or pulmonary impairment.
IV Injection	None listed for acute malignant hyperthermia crisis, as the life-saving need overrides other risks.

Special Population Restrictions:

Age: The oral capsule is generally not recommended/established for use in children under 5 years of age. Females and patients over 35 years using the oral form are at a statistically greater risk of hepatotoxicity. The IV injection is indicated for patients of all ages during a crisis.
Pregnancy/Lactation: Use during pregnancy is generally considered only if the potential benefit justifies the risk (US FDA Pregnancy Category C). Breastfeeding is not recommended or is contraindicated as the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dantrolene Sodium (Dantrelax) may interact with certain medicines and substances, leading to significant constraints on co-administration as defined in regulatory labeling. These interactions primarily involve effects on the central nervous system, cardiovascular stability, and liver function.

Contraindicated Combinations

Classification	Interacting Agents	Context/Constraint
Contraindicated	Intravenous Dantrolene and Calcium Channel Blockers (e.g., Verapamil)	Use is forbidden due to risk of cardiovascular collapse associated with hyperkalemia.

Other Clinically Significant Interactions

Classification	Interacting Agents/Substance	Documented Effect/Precaution
Additive Effect	CNS Depressants (e.g., Tranquilizers) and Alcohol	May cause increased drowsiness or dizziness (additive CNS depression).
Population-Specific Risk	Estrogen-containing products	Increased risk of hepatotoxicity (liver damage), particularly in women over 35 years of age.

Note on Metabolism: Investigations into co-administration with enzyme inducers like phenobarbital and diazepam found no significant alteration in the metabolism or elimination half-life of Dantrolene. Official regulatory documents also note a higher risk of fatal hepatic events in elderly patients compared to younger adults.

Mechanism of Action

Direct Inhibition of the Ryanodine Receptor (RyR1)

The mechanism of action for Dantrolene Sodium operates exclusively at the level of the skeletal muscle fiber via a direct, peripheral action, resulting in the modulation of excessive contractility. This action centers on the Ryanodine Receptor Type 1 ( RyR1), the key calcium ( Ca^2+) release channel located on the sarcoplasmic reticulum membrane. The drug acts as an inhibitor at this molecular target, limiting its capacity to release stored Ca^2+ into the muscle cell's interior.

Decoupling Excitation-Contraction Coupling (ECC)

This process describes the resulting cascade where the electrical impulse fails to produce a full mechanical response. By reducing the available Ca^2+ inside the myoplasm, the drug prevents the necessary interaction of actin and myosin filaments, functionally decoupling the electrical signal from the physical contraction. This targeted intervention results in the physiological consequence of decreased skeletal muscle contractile force without altering central nerve activity.

Dosage and Administration Information

The administration of Dantrolene Sodium is strictly defined by its clinical application, employing either the oral capsule for ongoing management or the intravenous (IV) powder for solution for critical care. The oral route is primarily designated for chronic spasticity management, while the IV route is reserved for acute Malignant Hyperthermia (MH) crisis or pre-operative prophylaxis.

For the long-term management of chronic spasticity in adults, the protocol involves initiating treatment with an initial dose of 25 mg once daily for seven days. The daily dose is progressively increased weekly, in divided amounts, up to a maximum maintenance dose of 100 mg four times a day (400 mg total daily). Oral capsules may be administered without regard to food. The protocol includes a trial period, and if no functional benefit is confirmed after 45 to 60 days, the regimen must be discontinued.

Conversely, the acute treatment of an MH crisis requires rapid IV administration starting at a minimum dose of 1 mg/kg, which may be repeated to a total cumulative dose of 10 mg/kg until physiological control is achieved. The powder must be carefully reconstituted solely with sterile water for injection and must be used within six hours of preparation. Following an acute crisis, the administration protocol mandates continued therapy for one to three days (72 hours) to support stability. Pediatric dosing for MH follows the same weight-based protocol as the adult regimen.

Recent Clinical Evidence

Evidence for Use in Chronic Muscle Spasticity

Dantrolene Sodium was studied for use in conditions marked by functional limitations, such as severe muscle spasticity, which is characterized by muscle stiffness and involuntary movements. The available evidence includes controlled clinical trials and long-term observational studies that tracked patterns over defined time intervals. Research examined changes in objective measures of muscle overactivity, such as muscle tone and clonus. While studies monitored these physical signs, findings were mixed regarding whether changes in objective measurements was associated with corresponding changes in outcomes reflecting daily functioning or activity level.

Evidence for Use in Acute Malignant Hyperthermia (MH) Crisis

The evidence base for Dantrolene Sodium was studied for use in conditions associated with acute or disruptive episodes, such as an Acute Malignant Hyperthermia (MH) crisis. The structure of this evidence is distinct, as Randomized Controlled Trials (RCTs) were not conducted for ethical reasons. Instead, research relies on extensive clinical experience, case series, and multicenter retrospective studies. Data show patterns related to the availability and timely administration of this medicine was associated with a significant contrast between historical survival rates and survival rates reported during the study period. This body of evidence contributes to understanding symptom patterns and is used in research contexts involving episodes where symptoms become more noticeable.

Study Limitations and Uncertainty

For spasticity, long-term effects are not fully established across the entire population, though some follow-up durations were limited to periods extending up to two years. Furthermore, data are still emerging for certain groups, such as young children under five years of age. A key gap noted in peer-reviewed literature is that comparative evidence is lacking for studies examining this use since its initial development period. For the acute crisis, the evidence is limited to retrospective data and case reports, meaning the evidence structure is not based on controlled clinical trials. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Dantrelax (FAQ)

Q: Can Dantrelax be taken at the same time as my regular vitamin supplements?

Official drug labeling documents do not list specific interactions with common vitamin supplements. However, the product information does caution about the risk of additive central nervous system (CNS) depression when Dantrelax is combined with other CNS depressants. It is important to review all co-administered products with a healthcare provider for full clarity on specific combinations.

Q: Is Dantrelax available in a generic version?

Yes, the active ingredient, Dantrolene Sodium, is available in generic formulations that have been approved by regulatory bodies like the FDA. These generic capsule formulations are commonly available in strengths such as 25 mg, 50 mg, and 100 mg.

Q: Do children ever get prescribed Dantrelax for certain conditions?

Regulatory documents indicate that the intravenous form of Dantrolene Sodium is indicated for use in pediatric patients of all ages for the treatment of an acute Malignant Hyperthermia crisis. The oral capsule form for chronic spasticity is generally recommended for use in children who are 5 years of age and older, in line with the dosage guidelines established in the official prescribing information.

Q: Does taking Dantrelax impact fertility or reproductive health?

Studies conducted in animals noted an increase in certain types of tumors, including mammary and testicular tumors. However, the official prescribing information states that the significance of this data relative to use in humans is unknown. Questions about fertility, family planning, or reproductive health should be discussed with a qualified healthcare professional.

Q: How quickly should I start to notice any effect from taking Dantrelax?

For the management of chronic muscle spasticity, official guidance describes a protocol that involves a gradual increase in dose over several weeks. Prescribing information requires that the regimen must be discontinued if no functional benefit is observed after a total trial period of 45 to 60 days. This indicates that a full evaluation of benefit may take several weeks.

Q: How long does Dantrelax stay in your system after you stop taking it?

Following intravenous administration for an acute crisis, the physiological effects may continue for a period. Official data suggests some documented side effects, such as dizziness and somnolence (drowsiness), may be observed for up to 48 hours post-dose.

Q: Are there different strengths of Dantrelax available?

Yes, the oral capsule formulations of Dantrolene Sodium are commercially manufactured and available in multiple strengths. Regulatory information specifies that these capsules are available in 25 mg, 50 mg, and 100 mg strengths.

Q: Does the time of day matter when taking Dantrelax?

Official guidance for chronic spasticity states that oral capsules may be administered without regard to food, allowing flexibility around meal times. For use in preventing Malignant Hyperthermia, the last dose is scheduled for administration approximately 3 to 4 hours before the planned surgical procedure.

Q: Are there any known drug-disease interactions for Dantrelax?

Official labeling identifies certain health conditions that require significant caution or prevent use. For example, the oral form is strictly contraindicated in patients with active hepatic (liver) disease. Caution is also advised for individuals with significantly impaired cardiac or pulmonary (lung) function.

Q: How does Dantrelax compare to older medicines used for the same purpose?

Regulatory documents indicate that there is a noted lack of comparative evidence from clinical studies examining Dantrolene Sodium for spasticity use since its initial development. Therefore, official data does not provide direct comparisons to other medicines used for the same purpose.

Q: Why do some people report feeling 'foggy' on Dantrelax?

This subjective feeling may be associated with common nervous system side effects described in official regulatory labeling. These documented adverse reactions include drowsiness (somnolence), dizziness, and speech disturbance (dysphonia).

Q: What is the purpose of the 'inactive ingredients' listed in Dantrelax?

Inactive ingredients are used for various manufacturing and functional purposes. For instance, the intravenous form of the medicine is officially noted to contain Mannitol, which assists in the dissolution of the powder and is medically classified as a diuretic.

Q: Can alcohol consumption interfere with the effectiveness of Dantrelax?

Official labeling notes that using alcohol with Dantrolene may cause increased drowsiness or dizziness. This is due to an additive central nervous system (CNS) depressant effect, which is a factor to consider when assessing the ability to safely perform activities that require concentration.

Q: What should be done if someone accidentally takes too much Dantrelax?

Overdose symptoms can include muscle weakness, vomiting, diarrhea, and alterations in consciousness, such as lethargy or coma. Regulatory guidance states that for suspected overdose, patients must contact a poison control center or seek emergency medical services.

Q: Is Dantrelax ever used to treat conditions other than muscle spasms?

Yes, besides its use in controlling muscle spasticity, regulatory documents indicate that Dantrolene Sodium is also officially indicated for the treatment and prevention of Malignant Hyperthermia (MH) crisis. This acute use is distinct from the chronic management of muscle spasticity.

Q: Does official prescribing information for Dantrelax mention its use in athletes?

While the main approved uses are spasticity and Malignant Hyperthermia, the intravenous form of Dantrolene Sodium has been granted Fast Track designation by the FDA for investigational use. This investigational use is to treat Exertional Heat Stroke (EHS), a condition relevant to specific physical activities.

How should Dantrelax be stored and disposed of?

How to Store and Dispose of Dantrelax (Dantrolene Sodium)

Dantrolene Sodium storage and disposal must strictly follow official regulatory requirements to ensure product stability and integrity.

Storage Requirements

Product Form	Temperature and Environment	Stability and Handling
Oral Capsules	Store not above 30 C, away from light and moisture.	Keep in the original outer packaging/blister packs; do not freeze.
Powder for Injection	Store at 20 C to 25 C (Controlled Room Temperature); avoid prolonged light exposure.	The reconstituted solution must be used within 6 hours and must not be refrigerated.